International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
SARS-CoV-2 Seroprevalence and Antibody Dynamics in The Gambia During the Transition from Pandemic to Endemic Circulation - 2022 and 2023.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Janha Ramatoulie E, Bah Alasana, Sonko Bakary, Mohammed Nuredin I, Faye-Joof Tisbeh, Bah Babatam, Jaiteh Lamin, Bah Lamin, Gomez David, Gaye Yassin, Keita Saikou, Sambou Sarata, Camara Lamin, Patterson Catriona, Vasileva Hristina, Ndiath Mamadou O, Ezeani Esu, Usuf Effua, Tetteh Kevin, Drakeley Chris, D'Alessandro Umberto, de Silva Thusan, Roca Anna
Аннотация
OBJECTIVES: To understand population-level seroprevalence once SARS-CoV-2 becomes endemic.
METHODS: We conducted two cross-sectional-sero-surveys (CSS) in three Health and Demographic Surveillance Systems (HDSS) in The Gambia: Farafenni, Basse and Kiang West. Dried blood spots were collected from 3909 participants in CSS1_2022 and 3991 in CSS2_2023, aged ≥1-year. SARS-CoV-2-spike (S-IgG) and nucleocapsid (NCP-IgG) proteins were measured by ELISA in both CSSs, while antibodies to SARS-CoV-2 variants and other respiratory viruses were quantified by multiplex-Luminex in CSS2_2023. Another CSS was conducted in Kiang West (KW survey) 3-months after CSS1_2022 to assess antibody dynamics. Statistical analysis was done using Stata/SE19.5.
RESULTS: S-IgG seroprevalence increased between CSS1_2022 and CSS2_2023 [88.1% 95%CI (86.3, 89.6) vs. 93.1% (92.0, 94.0), p<0.0001], whereas NCP-IgG seroprevalence declined [72.7% (70.7, 74.7) vs 61.7% (59.3, 63.9), p<0.0001]. S-IgG seroprevalence was higher in vaccinated vs. unvaccinated individuals [CSS1_2022 [aOR = 3.11(1.85, 5.23)] and CSS2_2023 [2.01(1.18, 3.42)]. SARS-CoV-2 variants seroprevalence ranged between 50%-80%, while seroprevalence to other respiratory viruses was more heterogeneous. In the KW survey, S-IgG seroprevalence remained stable compared with CSS1_2022: 89.2% (85.3, 92.3), while NCP-IgG seroprevalence dropped from 73.1% (68.5, 77.3) to 61.2% (53.6, 68.4).
CONCLUSION: By 2022-2023, SARS-CoV-2 exposure in The Gambia was nearly universal. Still, COVID-19 vaccinated individuals showed highest seroprevalence.
METHODS: We conducted two cross-sectional-sero-surveys (CSS) in three Health and Demographic Surveillance Systems (HDSS) in The Gambia: Farafenni, Basse and Kiang West. Dried blood spots were collected from 3909 participants in CSS1_2022 and 3991 in CSS2_2023, aged ≥1-year. SARS-CoV-2-spike (S-IgG) and nucleocapsid (NCP-IgG) proteins were measured by ELISA in both CSSs, while antibodies to SARS-CoV-2 variants and other respiratory viruses were quantified by multiplex-Luminex in CSS2_2023. Another CSS was conducted in Kiang West (KW survey) 3-months after CSS1_2022 to assess antibody dynamics. Statistical analysis was done using Stata/SE19.5.
RESULTS: S-IgG seroprevalence increased between CSS1_2022 and CSS2_2023 [88.1% 95%CI (86.3, 89.6) vs. 93.1% (92.0, 94.0), p<0.0001], whereas NCP-IgG seroprevalence declined [72.7% (70.7, 74.7) vs 61.7% (59.3, 63.9), p<0.0001]. S-IgG seroprevalence was higher in vaccinated vs. unvaccinated individuals [CSS1_2022 [aOR = 3.11(1.85, 5.23)] and CSS2_2023 [2.01(1.18, 3.42)]. SARS-CoV-2 variants seroprevalence ranged between 50%-80%, while seroprevalence to other respiratory viruses was more heterogeneous. In the KW survey, S-IgG seroprevalence remained stable compared with CSS1_2022: 89.2% (85.3, 92.3), while NCP-IgG seroprevalence dropped from 73.1% (68.5, 77.3) to 61.2% (53.6, 68.4).
CONCLUSION: By 2022-2023, SARS-CoV-2 exposure in The Gambia was nearly universal. Still, COVID-19 vaccinated individuals showed highest seroprevalence.